Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step
about
Mechanism and significance of cell type-dependent neutralization of flavivirusesVaccines in development against West Nile virusProgress on the development of therapeutics against West Nile virusProtonation of Individual Histidine Residues Is Not Required for the pH-Dependent Entry of West Nile Virus: Evaluation of the "Histidine Switch" HypothesisEffector Functions of Camelid Heavy-Chain Antibodies in Immunity to West Nile VirusThe Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityNeutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354Structural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic EpitopeStructure of the St. Louis Encephalitis Virus Postfusion Envelope TrimerStructural insights into the neutralization mechanism of a higher primate antibody against dengue virusCrystal Structure of the Japanese Encephalitis Virus Envelope ProteinThe structural basis for serotype-specific neutralization of dengue virus by a human antibodyPlant-made vaccines against West Nile virus are potent, safe, and economically feasibleEquine Immunoglobulin and Equine Neutralizing F(ab')₂ Protect Mice from West Nile Virus InfectionA single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesisVaccination strategies against Zika virusEnhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin.Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assayAntibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization.2'-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivoDevelopment of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus.Antibody responses in humans infected with newly emerging strains of West Nile Virus in EuropeCurrent trends in West Nile virus vaccine development.Dissection of antibody specificities induced by yellow fever vaccinationAntibody-mediated neutralization of flaviviruses: a reductionist view.The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement.Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.Identification of human neutralizing antibodies that bind to complex epitopes on dengue virionsEvidence for a genetic and physical interaction between nonstructural proteins NS1 and NS4B that modulates replication of West Nile virusInduction of antigen-specific immune responses in mice by recombinant baculovirus expressing premembrane and envelope proteins of West Nile virus.Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus Vaccines.Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing.A role for Ifit2 in restricting West Nile virus infection in the brain
P2860
Q23032973-746376F6-9368-4E1F-B031-F954897CD780Q26999702-0AED9541-51AD-41F2-A633-91B04ED06F3AQ27489893-A36D298D-7D48-42BD-9594-F598876D18B0Q27490468-7C46705A-698C-4D6B-B8A4-6AA12C9A3AA9Q27490881-9C7725EE-6BB3-4665-A4CB-0FEED3EC104CQ27491317-2D83E0AC-ED25-4108-BED7-E1B91D03AA02Q27654848-812E0BD3-B6EB-4F7A-ADD6-782473F7B25AQ27665151-5A9CFA1A-DE96-4871-A6EB-6DB4C32F327FQ27674417-3800BA4F-DC49-4BDC-BB4D-2E2326EFA4EDQ27674868-B66DE21E-BACA-40D7-88FC-68162F8CEEE7Q27675965-61D9B361-CCA7-4F5A-88BA-D80ADAD47747Q27676100-7AC12C0D-F64A-45B3-BBAF-034FF94CF1EFQ27681306-AC0ACF0C-61EC-4D23-8272-B653AB9A15B7Q28082778-8D1F1109-0052-493B-870E-368CE10833A9Q28353948-331130E0-85E1-40A8-9EDE-F0EF9523FA03Q28804076-ED8333DF-0C57-44E8-A6E8-2CF68BFE577BQ29571224-CB62A168-901D-4400-82CF-29E5E090B355Q33911897-FD7CA3DA-2EFE-490A-8B53-88101E75EE74Q33945441-22F2C62A-791F-4D33-9EE1-E9D99154AE1BQ34089838-72367671-EC27-46E8-979D-98E9A928764BQ34120070-3B0D2DCD-CB77-40C5-9603-5F94A01A14EFQ34123956-5C8E05DB-635B-4B4C-BB60-E328D6EDAD8CQ34237174-C0EEFB51-EAB0-4053-89F2-750128CCD3BAQ34270459-CCA1C2C0-6DF0-40C2-9B11-959DBFA8ED86Q34291876-A1A4D8D9-5AC6-4AFD-8A52-304045F55190Q34306877-0AC4701A-F822-4372-8534-F782A4E703F9Q34529911-2687A6F8-C439-4075-97D6-DF753AC04C62Q34776746-8279973B-0026-441B-82FD-B28103D3A337Q34788758-D00DBE2B-2C0B-4AB9-8D86-83B7278BE3E9Q34789343-01E20D9A-DCB6-48EE-ABFD-E922733EE8A9Q34999617-D74FA65D-176D-43E1-B9A2-D8692CCBD9EAQ35069160-2DF32C76-E156-4CAF-A9CE-C8527DDCD4A2Q35152094-6AD72457-B598-4DB6-A338-A58471A4C149Q35531167-4C6CAE09-6784-4CA0-B678-7413BF809CB8Q35982791-4C6BBD82-62FD-4A16-A078-D3E1DA820F6BQ36155471-FCDD5409-0677-45CF-91C7-1B3C052D5A83Q36179005-E98E71AD-5CB7-4C9D-BDD1-53E04DCD6468Q36524044-C613709A-12D6-4A3A-93AF-D53386CF98A7Q36584038-7631CD07-BB7F-4C78-8790-1A503B46173FQ37036707-49C8D705-9D97-4747-B819-37BEC4DB6814
P2860
Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step
description
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
article scientifique (publié 2009-07)
@fr
articolo scientifico (pubblicato il 2009-07)
@it
artigo científico (publicado na 2009-07)
@pt
artículu científicu espublizáu en 2009
@ast
im Juli 2009 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: July 2009)
@en
vedecký článok (publikovaný 2009-07)
@sk
vetenskaplig artikel (publicerad på 2009-07)
@sv
name
Human Monoclonal Antibodies ag ...... alize at a Postattachment Step
@ast
Human Monoclonal Antibodies ag ...... alize at a Postattachment Step
@en
Human Monoclonal Antibodies ag ...... alize at a Postattachment Step
@nl
type
label
Human Monoclonal Antibodies ag ...... alize at a Postattachment Step
@ast
Human Monoclonal Antibodies ag ...... alize at a Postattachment Step
@en
Human Monoclonal Antibodies ag ...... alize at a Postattachment Step
@nl
prefLabel
Human Monoclonal Antibodies ag ...... alize at a Postattachment Step
@ast
Human Monoclonal Antibodies ag ...... alize at a Postattachment Step
@en
Human Monoclonal Antibodies ag ...... alize at a Postattachment Step
@nl
P2093
P2860
P50
P356
P1433
P1476
Human Monoclonal Antibodies ag ...... alize at a Postattachment Step
@en
P2093
Bastiaan Moesker
Mark Throsby
Matthew R Vogt
S Kyle Austin
Steevenson Nelson
P2860
P304
P356
10.1128/JVI.00286-09
P577
2009-07-01T00:00:00Z